Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OTQ923 · 1 trial · 1 indication
Number of participants with delayed adverse events including new secondary malignancies, new incidence or exacerbation of a prior autoimmune disorder, new incidence or exacerbation of a prior rheumatologic disorder, new hematologic disorder, and other adverse events considered to be related to OTQ923 therapy.
| Arm | Type | Description |
|---|---|---|
| OTQ923 | EXPERIMENTAL | Patients were administered OTQ923 while enrolled on the treatment protocol (CADPT03A12101). Patients enrolled on this LTFU study will not be administered any study treatment. |
| Name | Type | Description |
|---|---|---|
| OTQ923 | BIOLOGICAL | There is no treatment allocation. Patients administered were OTQ923 while enrolled on the treatment protocol CADPT03A12101 (NCT04443907) |
Inclusion Criteria: 1. Patients must have received gene therapy treatment from the parent treatment protocol (CADPT03A12101). 2. Patients must provide informed consent prior to their entry into this study. Exclusion Criteria: 1\. Completion of less than 1 year of safety follow-up in the treatment...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 5 | PHASE3 | Etavopivat Low dose |
| Novartis AG Sponsored ADR | NVS | 4 | PHASE3 | Crizanlizumab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE3 | PCV21, 20vPCV |
| Vertex Pharmaceuticals Incorporated | VRTX | 3 | PHASE3 | CTX001 |
| Agios Pharmaceuticals, Inc. | AGIO | 2 | PHASE2 | Mitapivat |
| Pfizer Inc. | PFE | 1 | PHASE2 | Osivelotor |
| Bristol-Myers Squibb Company | BMY | 1 | PHASE1 | BMS-986470, Famotidine, Pantoprazole |
| Fulcrum Therapeutics, Inc. | FULC | 1 | PHASE2 | Pociredir |
| Beam Therapeutics, Inc. | BEAM | 2 | PHASE1 | BEAM-101 |
| Editas Medicine, Inc. | EDIT | 2 | PHASE1 | EDIT-301 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-3405 |
| Illumina, Inc. | ILMN | 1 | - | Undisclosed |
OTQ923 is an investigational therapy being studied for the treatment of Sickle Cell Disease. It is currently in Phase 1 clinical development, with an active long-term follow-up trial enrolling adult patients in the United States. The therapy is not yet approved and remains under investigation.
OTQ923 is being developed by Novartis AG, a global pharmaceutical company traded on the New York Stock Exchange under the ticker NVS. The company is conducting a Phase 1 clinical trial to evaluate the therapy in patients with Sickle Cell Disease.
OTQ923 is in Phase 1 clinical development. It is an investigational therapy for Sickle Cell Disease and has not been approved by regulatory authorities. The ongoing Phase 1 trial is active but not recruiting participants, with a small enrollment of four patients.
OTQ923 is being studied in a single Phase 1 clinical trial registered as NCT06155500. This trial is a long-term follow-up study of patients treated with genome-edited autologous hematopoietic stem and progenitor cells, conducted in the United States for adults with Sickle Cell Disease.
OTQ923 is classified as a monoclonal antibody modality. It is being investigated for Sickle Cell Disease, a hematologic condition. The therapy is in Phase 1 clinical trials, and its mechanism of action has not been detailed in available information.